Profile data is unavailable for this security.
About the company
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
- Revenue in USD (TTM)0.00
- Net income in USD-25.91m
- Incorporated2009
- Employees10.00
- LocationAtossa Therapeutics Inc10202 5Th Avenue Ne, Suite 200SEATTLE 98125United StatesUSA
- Phone+1 (206) 588-0256
- Fax+1 (302) 636-5454
- Websitehttps://atossatherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lineage Cell Therapeutics Inc | 6.19m | -24.19m | 164.02m | 75.00 | -- | 2.40 | -- | 26.52 | -0.1342 | -0.1342 | 0.0343 | 0.3617 | 0.0577 | -- | 18.25 | 82,480.00 | -22.57 | -19.53 | -26.03 | -22.59 | 90.83 | 89.13 | -391.25 | -370.88 | -- | -- | 0.0017 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
Sangamo Therapeutics Inc | 12.28m | -249.68m | 168.10m | 405.00 | -- | 7.10 | -- | 13.69 | -1.38 | -1.38 | 0.0664 | 0.1138 | 0.0587 | -- | 7.45 | 30,313.58 | -119.44 | -26.09 | -153.51 | -31.04 | -- | -- | -2,033.68 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
Galectin Therapeutics Inc | 0.00 | -48.03m | 170.64m | 14.00 | -- | -- | -- | -- | -0.7831 | -0.7831 | 0.00 | -1.32 | 0.00 | -- | -- | 0.00 | -185.54 | -92.08 | -382.33 | -121.97 | -- | -- | -- | -- | -- | -8.59 | 8.29 | -- | -- | -- | -15.26 | -- | -- | -- |
Caribou Biosciences Inc | 33.11m | -123.44m | 170.79m | 158.00 | -- | 0.5501 | -- | 5.16 | -1.39 | -1.39 | 0.3763 | 3.44 | 0.0917 | -- | 15.61 | 209,576.00 | -34.17 | -- | -37.56 | -- | -- | -- | -372.78 | -- | -- | -1,231.11 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
Vaxart Inc | 13.93m | -75.66m | 178.04m | 109.00 | -- | 2.23 | -- | 12.78 | -0.4707 | -0.4707 | 0.0861 | 0.3518 | 0.1178 | -- | 5.80 | 127,779.80 | -64.01 | -49.60 | -73.18 | -54.86 | -- | -- | -543.21 | -1,398.00 | -- | -226.73 | 0.0507 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
Greenwich Lifesciences Inc | 0.00 | -10.22m | 178.11m | 3.00 | -- | 30.14 | -- | -- | -0.7942 | -0.7942 | 0.00 | 0.4496 | 0.00 | -- | -- | 0.00 | -112.41 | -36.43 | -123.67 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
Atossa Therapeutics Inc | 0.00 | -25.91m | 178.58m | 10.00 | -- | 2.23 | -- | -- | -0.2064 | -0.2064 | 0.00 | 0.6374 | 0.00 | -- | -- | 0.00 | -26.68 | -29.97 | -28.00 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
Achieve Life Sciences Inc | 0.00 | -27.54m | 180.98m | 22.00 | -- | 4.28 | -- | -- | -1.10 | -1.10 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -58.78 | -86.31 | -71.94 | -119.59 | -- | -- | -- | -- | -- | -11.79 | 0.294 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
CytoDyn Inc | 0.00 | -51.32m | 187.48m | 9.00 | -- | -- | -- | -- | -0.0527 | -0.0527 | 0.00 | -0.1103 | 0.00 | -- | -- | 0.00 | -444.45 | -259.15 | -- | -- | -- | -- | -- | -232,918.20 | -- | -2.76 | -- | -- | -- | -- | 35.70 | -- | -- | -- |
Pyxis Oncology Inc | 16.15m | -59.20m | 196.69m | 51.00 | -- | 1.15 | -- | 12.18 | -1.26 | -1.26 | 0.3269 | 2.88 | 0.0842 | -- | -- | 322,920.00 | -30.87 | -- | -33.12 | -- | 97.06 | -- | -366.67 | -- | -- | -- | 0.0008 | -- | -- | -- | 38.87 | -- | -- | -- |
Candel Therapeutics Inc | 0.00 | -49.99m | 197.32m | 42.00 | -- | -- | -- | -- | -1.70 | -1.70 | 0.00 | -0.321 | 0.00 | -- | -- | 0.00 | -117.35 | -- | -158.61 | -- | -- | -- | -- | -- | -- | -32.70 | 2.36 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
Kyverna Therapeutics Inc | -100.00bn | -100.00bn | 198.48m | 112.00 | -- | 0.5951 | -- | -- | -- | -- | -- | 7.73 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0042 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
DiaMedica Therapeutics Inc | 0.00 | -19.90m | 198.78m | 18.00 | -- | 3.72 | -- | -- | -0.5238 | -0.5238 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -33.49 | -45.38 | -34.98 | -48.24 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 5.71m | 4.54% |
Geode Capital Management LLCas of 30 Jun 2024 | 2.77m | 2.20% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.30m | 1.83% |
Laurion Capital Management LPas of 31 Mar 2024 | 2.23m | 1.77% |
Renaissance Technologies LLCas of 30 Jun 2024 | 1.55m | 1.23% |
Millennium Management LLCas of 31 Mar 2024 | 1.01m | 0.81% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 739.81k | 0.59% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 628.55k | 0.50% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 493.57k | 0.39% |
The Bank of New York Mellon Corp. (Investment Management)as of 30 Jun 2024 | 294.04k | 0.23% |